Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 228-234

  Chazot, Charles ^a   Terrat, Jean Claude ^b   Dumoulin, Alexandre ^c   Ang, Kim Seng ^d   Gassia, Jean Paul ^e   Chedid, Khalil ^f   Maurice, Francois ^g   Canaud, Bernard ^h  

^a Centre de dialyse   (France)

^b Centre de Rein Artificiel de Tassin   (France)

^c Centre d'Hémodialyse Languedoc Méditerranée   (France)

^d Centre Hospitalier Yves Le Foil   (France)

^e Centre Néphrologique d'Occitanie   (France)

^f Nephrocare Ile de France ^*  (France)

^g Centre Hemodialyse Languedoc Méditerranée   (France)

^h LAPEYRONIE HOSPITAL   (France)

Author keywords

Darbepoetin alfa; Hemodialysis; Recombinant human erythropoietin

Indexed keywords

FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; THERAPEUTIC EQUIVALENCY;

EID: 60349095142     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K664     Document Type: Article

References (21)

1. Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: improving global outcome. Kidney Int 2004;66:1310-4.
2. Macron-Nogues F, Vernay M, Ekong E, et al. The prevalence of ESRD treated with renal dialysis in France in 2003. Am J Kidney Dis 2005;46: 309-15.
3. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9.
4. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
5. Robinson DM, Easthope SE. Darbepoetin alfa. Its use in anemia associated with chronic kidney disease. Biodrugs 2005;19:327-43.
6. Molina M, Garcia Hernandez MA, Navarro MJ, De Gracia MC, Ortuno T. [Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha] Spanish. Nefrologia 2004;XXIV:564-71.
7. Summers S, Winnett G, Matijevic AM, Carmichael D, Almond M. An audit comparing subcutaneous epoetin alfa to intravenous darbepoetin alfa in chronic hemodialysis patients. Dial Transplant 2005;34:358-62.
8. Cervelli MJ, Gray N, McDonald S, Gentgall MG, Disney APS. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology 2005;10:129-35.
9. Shalansky K, Jastrzebski J. Complete switch to darbepoetin in a hemodialysis unit. Clin Nephrol 2005;64:55-63.
10. Aranesp (darbepoetin alfa). European summary of product characteristics. Breda, Netherlands: Amgen, April 2004.
11. Barker L, Rolka H, Rolka D, Brown C. Equivalence testing for binomial random variables: which test to use? American Statistician 2001;55:279-87.
12. Welcome to CTCAE dictionary. Http://safetyprofiler-ctep.nci.nih.gov/ Utilities/WebHelp/using-ctcae-dictionary/welcome-to-ctcae-dictionary.htm (accessed 2009 Jan 5).
13. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:662-3.
14. Galliford JW, Malsana R, Farrington K. Switching from subcutaneous to intravenous erythropoietin α in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant 2005;20:1956-62.
15. Linde T, Furuland H, Wikström B. Effect of switching from subcutaneous to intravenous administration of epoetin-α in haemodialysis patients: Results from a Swedish multicentre survey. Scand J Urol Nephrol 2005;39:329-33.
16. EMEA. ICH Topic E 9. Statistical principles for clinical trials. September 1998 (CPMP/ICH/363/96). § 3.3.2: Trials to show equivalence or non inferiority. Page 17. www.emea.europa.eu/pdfs/human/ich/036396en.pdf (accessed 2007 Nov 19).
17. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. Br Med J 1996;313:36-9.
18. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative Guidelines. www.kidney.org/professionals/kdoqi/guidelines-anemia/index.htm (accessed 2007 Nov 19).
19. Paoletti E, Cannella G. Update on erythropoietin treatment: should hemoglobin be normalized in patients with chronic kidney disease? J Am Soc Nephrol 2006;17(suppl 2):S74-7.
20. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:121-32.
21. Goodkin DA, Gimenez LF, Graber SE, Van Stone JC, Egrie JC, Okamoto DM. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis. Clin Nephrol 1999;51:367-72.